Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Accumulated Expenses (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Other Accumulated Expenses for 13 consecutive years, with $69.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 49.89% year-over-year to $69.1 million, compared with a TTM value of $69.1 million through Dec 2025, up 49.89%, and an annual FY2025 reading of $69.1 million, up 49.89% over the prior year.
  • Other Accumulated Expenses was $69.1 million for Q4 2025 at Neurocrine Biosciences, up from $53.7 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $69.1 million in Q4 2025 and bottomed at $18.1 million in Q1 2021.
  • Average Other Accumulated Expenses over 4 years is $36.1 million, with a median of $36.7 million recorded in 2024.
  • The sharpest move saw Other Accumulated Expenses grew 25.69% in 2021, then skyrocketed 99.46% in 2024.
  • Year by year, Other Accumulated Expenses stood at $20.0 million in 2021, then skyrocketed by 79.5% to $35.9 million in 2023, then grew by 28.41% to $46.1 million in 2024, then soared by 49.89% to $69.1 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for NBIX at $69.1 million in Q4 2025, $53.7 million in Q3 2025, and $56.8 million in Q2 2025.